Study includes largest cohort to date
Multigene panel testing valuable regardless of age, cancer history
Prescreening for clots also effective
Should lead to better treatment
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
High-risk and real-world patients responded
Study explores atezolizumab for myelodysplastic syndrome
FDA approval may come in 2019
Lower toxicity than conventional chemo
Groundbreaking study paves way for targeted therapy
Gene signatures differentiate clinical response
Advertisement
Advertisement